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Objectives: Pathological gambling (PG) is a highly prevalent and disabling impulse control
disorder. A range of psychopharmacological options are available for the treatment of PG,
including selective serotonin reuptake inhibitors, opioid receptor antagonists, anti-addiction
drugs, and mood stabilizers. In our preliminary study, we examined the efﬁcacy of two
anti-addiction drugs, baclofen and acamprosate, in the treatment of PG. Materials and
Methods: Seventeen male gamblers were randomly divided into two groups. Each group
received one of the two drugs without being blind to treatment. All patients underwent a
comprehensive psychiatric diagnostic evaluation and completed a series of semi-structured
interviews. During the 6-months of study, monthly evaluations were carried out to assess
improvement and relapses. Relapse was deﬁned as recurrent gambling behavior. Results:
None of the 17 patients reached the 6-months abstinence. One patient receiving baclofen
sustained abstinence for 4months. Fourteen patients succeeded in sustaining abstinence
for 1–3months.Two patients stopped attendingmonthly evaluations.Conclusion:Baclofen
and acamprosate did not prove efﬁcient in treating pathological gamblers.
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INTRODUCTION
Pathological gambling (PG) is classiﬁed in the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition, as an impulse
control disorder (American Psychiatric Association, 2000). In the
International Classiﬁcation of Diseases of the World Health Orga-
nization, PG is considered a habit and impulse disorder, alongside
kleptomania; trichotillomania, and pyromania, all of which are
characterized by an overwhelming urge to perform a harmful act
(World Health Organization, 1992). PG is a chronic, progressive,
male-dominant disorder, causing great personal and social con-
sequences such as suicide attempts, job loss, martial and family
problems, legal problems, and criminal behaviors (Dannon et al.,
2006; Iancu et al., 2008).
To date, a range of psychopharmacological options are avail-
able for the treatment of PG, including selective serotonin reup-
take inhibitors (SSRI), opioid receptor antagonists, anti-addiction
drugs, and mood stabilizers.
Multiple randomized, double-blind as well as open-label short-
term (8, 12, or 16-week) trials have assessed pharmacotherapy
for the acute treatment of PG. As a group, these trials show an
overall mixed success with several double-blind studies failing to
show short-term efﬁcacy. To date, there have been four double-
blind trials of SSRIs for the treatment of PG. While two studies
showed short-term efﬁcacy (Hollander et al., 2000; Kim et al.,
2002), separate studies by Blanco et al. (2002) and Grant et al.
(2003) found no signiﬁcant statistical superiority of the SSRI agent
when compared to a placebo. Preliminary studies have examined
the use of the mood stabilizers, topiramate (Dannon et al., 2005a),
and anti-addiction drug, bupropion (Black, 2004; Dannon et al.,
2005b,c), for the short-term treatment of PG with most studies
showing a beneﬁcial effect. In addition, the anti-addiction, opioid
antagonist naltrexone, has been shown to be beneﬁcial in treating
the cravings and urges associated with PG (Kim and Grant, 2001;
Kim et al., 2001).
It is well accepted in the clinical literature of PG that there are
several important limitations of existing short-term medication
trials: (1) variable rates of placebo response have been demon-
strated in the short-term studies, raising the question of whether
improvement seen in treatment groups may be related to non-
medication mechanisms of action; (2) PG typically has a chronic
course, and therefore acute remission of symptoms may not lead
to a clinically signiﬁcant improvement in functioning if the remis-
sion is not sustained; and (3) in all short-term studies published to
date, remission of gambling symptoms was judged, at least in part,
according to patients’ self-reports of gambling behaviorwhichmay
be biased (Dannon et al., 2007).
The opioid system controls the processing of reward, pleasure,
and pain, alongside gambling-related urges. Data suggests that
opioid receptor antagonists mediate their therapeutic action in
the treatment of addictive disorders through the modulation of
GABA neuronal input to dopamine neurons in the mesolimbic
pathway (Kim and Grant, 2001; Kim et al., 2001). GABA rep-
resents the main inhibitory neurotransmitter in the brain. High
levels of GABAB receptor expression in the limbic system indicate
a role in regulating emotional behavior (Addolorato et al., 2009).
The assumption is being that the GABA receptors may play a role
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in the pattern of urges, craving, and sense of enjoyment seen in
PG behavior (Addolorato et al., 2009).
The brain’s reward circuit, located in the nucleus accumbens,
ensures reinforcement of behaviors associated with species sur-
vival and procreation. The opioid system is involved in the process
of reward, pleasure, pain, and gambling-related urges. It has been
suggested that opioid receptor antagonists mediate their thera-
peutic action in the treatment of addictive disorders through the
modulation of GABA neuronal input to dopamine neurons in the
mesolimbic pathway (Addolorato et al., 2009). The above data
had led us to believe that GABA directed addiction drugs, such
as baclofen and acamprosate, might be efﬁcient in the treatment
of PG.
Alcohol has been proven to affect GABA neurotransmitters in
the brain, and anti-addiction drugs have been shown to be efﬁcient
in decreasing the consumption and craving of alcohol. Acam-
prosate is believed to increase the effect on the inhibitory neu-
rotransmitter GABA and to decrease excitatory glutamate activity
at NMDA receptors (Addolorato et al., 2009). Baclofen is known
to suppress alcohol-stimulated dopamine release in the shell of
the nucleus accumbens of rats (Addolorato et al., 2009), and its
administration has been shown to promote alcohol abstinence
and reduce alcohol craving and intake; it has also been shown to
reduce anxiety (Addolorato et al., 2006).
Previous experience with anti-addiction medications, such as
bupropion and naltrexone, has been shown to be themost effective
for the treatment of PG (Kim and Grant, 2001; Kim et al., 2001;
Black, 2004; Dannon et al., 2005b,c). Based on the effectiveness
of anti-addiction drugs, we examined the efﬁcacy of two other
medications, baclofen and acamprosate. The difference between
the two groups is the system on which the drug affects; while
bupropion and naltrexone affect the reward system and the neuro-
transmitter dopamine, the baclofen, and acamprosate could affect
the GABA system.
In our study, we tested the efﬁcacy of two addiction drugs,
acamprosate and baclofen, which stimulate the GABA receptors,
and have been proven to be effective in the treatment of alcohol
abuse (Addolorato et al., 2009).
1 Acamprosate
Acamprosate (calcium acetylhomotaurinate) is a simple deriv-
ative of the essential taurine amino acid which displays a
structural resemblance to gamma-amino butyric acid (GABA;
American Psychiatric Association, 2000). It was approved by the
US FDA in 2004 for treatment of alcoholic patients to decrease
alcohol craving after alcohol detoxiﬁcation. Acamprosate seems
to bind speciﬁcally to GABAB receptors (Boothby and Doer-
ing, 2005). It enhances GABA reception and the transmission of
the GABAergic system, raises the continuous alcohol abstinence
rate and doubles the days of cumulative abstinence from alco-
hol (Boothby andDoering, 2005).Acamprosate is not a sedative;
it does not possess addictive properties or provide reinforcing
effects.
2 Baclofen
Baclofen [beta-(4-chlorophenyl)-GABA] is a GABAB receptor
agonist that has been found to suppress both acquisition of
alcohol drinking behaviors in rats and daily alcohol intake in
alcohol experienced rats. It also suppresses alcohol-stimulated
dopamine released in the shell of the nucleus accumbens of rats
(Addolorato et al., 2009).
In alcohol dependant subjects, baclofen administration pro-
motes alcohol abstinence, induces the remission of withdrawal
symptoms, and reduces alcohol craving and alcohol intake
(Addolorato et al., 2006).
MATERIALS AND METHODS
STUDY SUBJECTS
Patients were referred to our clinic, from ambulatory services
throughout Israel, on account of our gambling disorder expertise.
All study patients signed an informed consent form after possible
side effects of the study medications were explained to them. Cur-
rent study was approved by local IRB committee to publish the
results of clinical trial. Patients also gave consent for family mem-
bers to be interviewed at the monthly follow-up visits. Inclusion
criteria included: PG diagnosis according to DSM-IV-TR crite-
ria and South Oaks gambling scale (SOGS) score of more than 5.
Exclusion criteria included: co-morbiditywith axis one psychiatric
disorders,neurological disorders, alcohol and substance abuse,and
treatment with any psychiatric medication in the month before to
the screening interview.
All patients underwent a comprehensive psychiatric diagnostic
evaluation and completed a series of semi-structured interviews
performed by a senior psychiatrist (PND).
Study subjects were evaluated on a monthly basis throughout
the duration of the study in order to assess measures of sustained
improvement (i.e., abstinence) and relapse. In this study, absti-
nence was strictly deﬁned as no gambling behavior (including any
formof gambling) during themonthpreceding the follow-up visit.
Relapse was deﬁned as any gambling behavior during the month
preceding the follow-up visit.
Instruments
We administered the Hamilton rating scale for anxiety (HARS;
Hamilton, 1959), the Hamilton depression rating scale (HDRS;
Hamilton, 1959, 1960), visual analog scale (VAS; Guy, 1976), and
the South Oaks gambling screen (SOGS; Leisure and Blume, 1987)
at baseline.HARS,HDRS,VASwere administered at everymonthly
follow-up visit. The patients’ self-reports regarding amount of
time spent gambling was assessed at each follow-up visit although
a structured interview was not performed. Collateral information
regarding gambling behavior was collected from family members
at the monthly follow-up visits. All scales were administered by
the rater (TL) who was blind to drug treatment.
MEDICATION
Patients were randomly assigned to treatment with baclofen or
acamprosate. Treatment with baclofen was conducted as follows:
10mg per day for the ﬁrst 4 days, than 20mg for the next 4 days,
and than 30mg with stable condition up to 3weeks. Average
dosage of baclofen was 30mg per day (SD+ 7.5). Some patients
were treated with up to 50mg per day.
Treatment with acamprosate was conducted as follows: 333mg
for the ﬁrst 4 days than 666mg for a week and afterward 999mg
per day. Average dosage of acamprosate was 666mg (SD+ 174).
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Analysis
Statistical analysis was performed with t -test and ANOVA analy-
ses. Levels of signiﬁcance were set at 0.05, unless otherwise stated.
Also, two tailed t -test was chosen to perform a part of the statistical
analysis for independent samples.
RESULTS
Patients’ ages ranged between 19 and 69 years (29.6± 16.5).
Demographic data are summarized in Table 1.
The average SOGS score was 7.4+ 2.8 at baseline visit in two
groups. Also, HDRS, HARS, and VAS average scores were similar
and summarized in Table 2.
According to treatment regimensT -test comparison has shown
no statistical differences in HDRS, HARS, or VAS (Table 3).
Also, ANOVA analyses of VAS scores of patients treated with
either medication at baseline, after 1month and at relapse has
Table 1 | Demographic characteristics of the patients.
Baclofen
(N =9)
Acamprosate
(N =8)
P
values
Age 29.7±13.5 30.4±11.9 NS
Ethnicity %
North African decent 46 50% NS
Eastern European decent 30% 24% NS
Israeli born 24% 26% NS
Education %
12th grade 40% 40% NS
High School diploma 36% 40% NS
University 24% 20% NS
Employment %
Unemployed 18% 16% NS
Full/part time 82% 84% NS
Marital status %
Married 70% 66% NS
Widowed–divorced–separated 18% 20% NS
Never married 12% 14% NS
Table 2 | Statistical comparison of HDRS, HARS, andVAS scores of
patients treated with acamprosate and baclofen.
Visual
analog
scale
Hamilton
depression
rating
scale
Hamilton
anxiety
rating
scale
UnpairedT -TEST
at baseline
P >0.74 P >0.86 P >0.78
UnpairedT -TEST
after 1month of
treatment
completion
P >0.73 P >0.9 P >0.1
UnpairedT -TEST
at the time of
relapse
P >0.3 P >0.9 P >0.97
HDRS, Hamilton depression rating scale; HARS, Hamilton anxiety rating scale;
VAS, visual analog scale.
shown no statistical differences (P = 0.9; f = 0.3; lambda= 1.5;
power= 0.1).
ANOVA analyses of HDRS scores of patients treated with
either medication at baseline, after 1month and at relapse has
shown no statistical differences (P = 0.92; f = 0.26; lambda= 1.3;
power= 0.1).
ANOVA analyses of HARS scores of patients treated with
either medication at baseline, after 1month and at relapse has
shown no statistical differences (P = 0.38; f = 1.1; lambda= 5.4;
power= 0.3).
SIDE EFFECTS
Baclofen induced side effects were: weakness, apathy, headaches,
nausea. Acamprosate induced side effects included: nausea, vom-
iting head aches, muscle aches, stiffness. None of the patients
stopped the medication due these mild side effects.
DISCUSSION
None of the subjects from both groups succeeded to complete the
6-months of abstinence from gambling, we conclude that these
two medications were not effective to stop the gambling behavior.
However, recently published case report showed the effectiveness
of acamprosate. In this case patient was addicted to alcohol and
gambling (Raj, 2010).
We postulate that the GABA system, in oppose to the reward
system,most likely, does not have a major role in manifesting gam-
bling in the PG. Dannon et al. (2006) and Iancu et al. (2008) have
reviewed PG literature and have suggested a comprehensive theory
of PG typology and treatment ramiﬁcations of each PG subtype.
Therefore, this model was further used in this study as it may well
beneﬁt treatment efﬁcacy for PG.
Dannon et al. (Dannon et al., 2006; Iancu et al., 2008) identiﬁed
a typology consisting of threePG subtypes: (1) addictive PG,which
is the largest subtype characterized by moderate severity of PG,
increase alcohol abuse and dependence and being predominantly
male. This subtype is suggested to best beneﬁt from opioid antag-
onists and anti-addiction drugs, (2) an obsessive compulsive PG
which is characterized by being predominantly female gamblers;
onset tends to be in midlife in response to a perceived psycho-
logical trauma, increased mood and anxiety co-morbidity. These
patients may best beneﬁt from anti-depressants such as SSRIs and
SNRIs and from psychotherapy addressing stress resolution and
coping mechanisms, and (3) an impulsive PG subtype character-
ized by high levels of risk-taking behaviors, little ability to plan and
a tendency to spend large sums of money at one sitting. This sub-
type tends to present with alcohol abuse, attention deﬁcit disorder
(ADD) and other impulse control disorders. These patients may
respond best to lithium or other mood stabilizers/antiepileptic
drugs thought to target impulsive behavior.
The hypothetical model of sub typing is to explain the effec-
tiveness of differentmedications through different subtypes of PG.
In this preliminary study may have involved addicted subtype of
pathological gamblers but, may be the small sample size, could
not present equally all subtypes. However, the relatively low levels
of the patients ability to stop the gambling behavior more than a
month period demonstrates the ineffectiveness of these to drugs
in the treatment of gambling addiction.
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Table 3 | Average scores and SD of HDRS, HARS, andVAS.
Baclofen Acamprosate
Baseline After 1month At the time of relapse Baseline After 1month At the time of relapse
HDRS 10.1± 2 10.6± 1 10.6± 1.5 10.3± 1.5 10.7± 1.7 10.7± 1.2
HARS 11.25± 1.66905 11.75± 0.707 11.9± 0.64 11± 1.732 10.9± 1.21 11.9± 1.07
VAS 52.5± 11.6 51.8± 10.3 49.3± 6.2 54.3± 8.4 53.6± 8.5 52.8± 6.3
HDRS, Hamilton depression rating scale; HARS, Hamilton anxiety rating scale; VAS, visual analog scale.
The importance of pharmacological preliminary studies such
as our study ensues from the fact that no established pharma-
cotherapy exists. Potentially effective directions for future pharma-
cotherapy need to be explored on the basis of preliminary studies,
or alternatively, as in this case, be renounced.
LIMITATIONS
The small sample size of this study limits the power of the study.
Another limitation is patients were not blind to pharmacotherapy.
A third limitationwas the lack of amedication-free placebo control
group. However, since the results of this study indicate the inefﬁ-
cacy of both of the medications, this limitation does not lessen the
strength of this particular study. We do recommend that further
studies using a placebo-controlled design should be carried out in
order to conﬁrm our preliminary ﬁndings.
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